Literature DB >> 26156513

Inflammation-associated declines in cerebral vasoreactivity and cognition in type 2 diabetes.

Chen-Chih Chung1, Daniela Pimentel1, Azizah J Jor'dan1, Ying Hao1, William Milberg1, Vera Novak2.   

Abstract

OBJECTIVE: The aim of this prospective study was to investigate the relationships between inflammation, cerebral vasoregulation, and cognitive decline in type 2 diabetes mellitus (T2DM) over a 2-year span.
METHODS: Sixty-five participants (aged 66 ± 9.2 years, 35 with T2DM, 33 women) were enrolled for this 2-year prospective study. Continuous arterial spin labeling at 3-tesla MRI was used to measure global and regional cerebral perfusion and vasoreactivity. Neuropsychological measures were evaluated at the beginning and completion of the study. The associations between serum inflammatory markers, regional cerebral vasoreactivity, and cognitive functions were examined using least squares models.
RESULTS: After 2 years of follow-up, participants with T2DM had diminished global and regional cerebral vasoreactivity and a decline in multiple cognitive tasks compared with baseline (p < 0.0001-0.012). In the T2DM group, lower cerebral vasoreactivity was associated with a greater decrease in daily living activities score (r(2) adj = 0.35, p = 0.04), and lower global vasodilation was associated with a greater decline in executive function (r(2) adj = 0.6, p = 0.047). Higher serum soluble intercellular and vascular adhesion molecules, higher cortisol, and higher C-reactive protein levels at baseline were associated with greater decreases in cerebral vasoreactivity and vasodilation only in the T2DM group (r(2) adj = 0.16-0.53, p = 0.007-0.048), independent of diabetes control and 24-hour blood pressure. Higher glycated hemoglobin A1c levels were associated with a greater increase in vasoconstriction in the T2DM group.
CONCLUSIONS: Inflammation may further impair cerebral vasoregulation, which consequently accelerates decline in executive function and daily activities performance in older people with T2DM.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26156513      PMCID: PMC4534073          DOI: 10.1212/WNL.0000000000001820

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Etiology of differences in hematocrit between males and females: sequence-based polymorphisms in erythropoietin and its receptor.

Authors:  S M Zeng; J Yankowitz; J A Widness; R G Strauss
Journal:  J Gend Specif Med       Date:  2001

2.  Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging.

Authors:  J M Starr; J Wardlaw; K Ferguson; A MacLullich; I J Deary; I Marshall
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

Review 3.  Type 2 diabetes and cognitive impairment: linking mechanisms.

Authors:  José A Luchsinger
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  Cognitive dysfunction profile and arterial stiffness in type 2 diabetes.

Authors:  Shima Mehrabian; Margarita Raycheva; Antoaneta Gateva; Gergana Todorova; Petia Angelova; Martina Traykova; Tonya Stankova; Zdravko Kamenov; Latchezar Traykov
Journal:  J Neurol Sci       Date:  2012-08-05       Impact factor: 3.181

Review 5.  Endothelial dysfunction in human diabetes.

Authors:  Sari Mäkimattila; Hannele Yki-Järvinen
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

6.  Reliability and validity of composite scores from the NIH Toolbox Cognition Battery in adults.

Authors:  Robert K Heaton; Natacha Akshoomoff; David Tulsky; Dan Mungas; Sandra Weintraub; Sureyya Dikmen; Jennifer Beaumont; Kaitlin B Casaletto; Kevin Conway; Jerry Slotkin; Richard Gershon
Journal:  J Int Neuropsychol Soc       Date:  2014-06-24       Impact factor: 2.892

7.  Cerebral vasoreactivity in hypocapnia and hypercapnia in patients with diabetes mellitus type 2 with or without arterial hypertension.

Authors:  Anetta Lasek-Bal; Zofia Kazibutowska; Anna Gołba; Ewa Motta
Journal:  Neurol Neurochir Pol       Date:  2012 Nov-Dec       Impact factor: 1.621

8.  Relations of arterial stiffness and endothelial function to brain aging in the community.

Authors:  Connie W Tsao; Sudha Seshadri; Alexa S Beiser; Andrew J Westwood; Charles Decarli; Rhoda Au; Jayandra J Himali; Naomi M Hamburg; Joseph A Vita; Daniel Levy; Martin G Larson; Emelia J Benjamin; Philip A Wolf; Ramachandran S Vasan; Gary F Mitchell
Journal:  Neurology       Date:  2013-08-09       Impact factor: 9.910

Review 9.  Update on cognitive decline and dementia in elderly patients with diabetes.

Authors:  L Bordier; J Doucet; J Boudet; B Bauduceau
Journal:  Diabetes Metab       Date:  2014-04-02       Impact factor: 6.041

10.  Adhesion molecules, altered vasoreactivity, and brain atrophy in type 2 diabetes.

Authors:  Vera Novak; Peng Zhao; Brad Manor; Ervin Sejdic; David Alsop; Amir Abduljalil; Paula K Roberson; Medha Munshi; Peter Novak
Journal:  Diabetes Care       Date:  2011-09-16       Impact factor: 19.112

View more
  35 in total

1.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

2.  Humans with Type-2 Diabetes Show Abnormal Long-Term Potentiation-Like Cortical Plasticity Associated with Verbal Learning Deficits.

Authors:  Peter J Fried; Lukas Schilberg; Anna-Katharine Brem; Sadhvi Saxena; Bonnie Wong; Aaron M Cypess; Edward S Horton; Alvaro Pascual-Leone
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Cerebrovascular complications of diabetes: focus on cognitive dysfunction.

Authors:  Trevor Hardigan; Rebecca Ward; Adviye Ergul
Journal:  Clin Sci (Lond)       Date:  2016-10-01       Impact factor: 6.124

4.  Cognitive deficits in non-demented diabetic elderly appear independent of brain amyloidosis.

Authors:  Gloria C Chiang; Eileen Chang; Sneha Pandya; Amy Kuceyeski; James Hu; Richard Isaacson; Christine Ganzer; Aaron Schulman; Vivian Sobel; Shankar Vallabhajosula; Lisa Ravdin
Journal:  J Neurol Sci       Date:  2016-11-17       Impact factor: 3.181

5.  Cognitive decline in metabolic syndrome is linked to microstructural white matter abnormalities.

Authors:  Freddy J Alfaro; Vasileios-Arsenios Lioutas; Daniela A Pimentel; Chen-Chih Chung; Francisco Bedoya; Woo-Kyoung Yoo; Vera Novak
Journal:  J Neurol       Date:  2016-10-11       Impact factor: 4.849

6.  Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus.

Authors:  Chen-Chih Chung; Daniela A Pimentel Maldonado; Azizah J Jor'dan; Freddy J Alfaro; Vasileios-Arsenios Lioutas; Maria Zunilda Núñez; Vera Novak
Journal:  J Neurol       Date:  2018-07-30       Impact factor: 4.849

7.  Effects of very low-carbohydrate vs. high-carbohydrate weight loss diets on psychological health in adults with obesity and type 2 diabetes: a 2-year randomized controlled trial.

Authors:  Naomi Kakoschke; Ian T Zajac; Jeannie Tay; Natalie D Luscombe-Marsh; Campbell H Thompson; Manny Noakes; Jonathan D Buckley; Gary Wittert; Grant D Brinkworth
Journal:  Eur J Nutr       Date:  2021-05-20       Impact factor: 5.614

Review 8.  White matter microstructure and cognitive decline in metabolic syndrome: a review of diffusion tensor imaging.

Authors:  Freddy J Alfaro; Anna Gavrieli; Patricia Saade-Lemus; Vasileios-Arsenios Lioutas; Jagriti Upadhyay; Vera Novak
Journal:  Metabolism       Date:  2017-09-08       Impact factor: 8.694

9.  Diabetes-Related Cognitive Decline, a Global Health Issue, and New Treatments Approaches.

Authors:  Vera Novak; Federico Gomez; Alexandre Campos Dias; Daniela A Pimentel; Freddy J Alfaro
Journal:  Int J Priv Health Inf Manag       Date:  2017 Jul-Dec

10.  The resting perfusion pattern associates with functional decline in type 2 diabetes.

Authors:  Weiying Dai; Wenna Duan; Freddy J Alfaro; Anna Gavrieli; Fotini Kourtelidis; Vera Novak
Journal:  Neurobiol Aging       Date:  2017-09-14       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.